Current epidemiology of pertussis in Japan

Kimura, Mikio; Kuno-Sakai, Harumi

doi:10.1097/00006454-199010000-00004

Cited by 34 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4) As a result, the incidence of pertussis fell again, reaching about 0.4 cases per 100000 population in 1988. 2,3) The incidence of pertussis fell still further, to close to zero cases per 100000 population, in 1998.…”

Section: Introductionmentioning

confidence: 99%

“…In the 1960's, the introduction of pertussis vaccine in combination with diphtheria toxoid (DwP) and then with tetanus toxoid (DTwP) resulted in higher rates of acceptance of pertussis vaccine. 2) As a result, the annual number of reported cases of pertussis stabilized at levels of less than 0.5 cases per 100000 population until the early 1970's. 2,3) However, because of adverse reactions of DTwP in 1974 and 1975, mass vaccinations were temporarily suspended in 1975, 2) and the incidence of pertussis rose to 11.3 cases per 100000 population in 1979.…”

Section: Introductionmentioning

confidence: 99%

“…2) As a result, the annual number of reported cases of pertussis stabilized at levels of less than 0.5 cases per 100000 population until the early 1970's. 2,3) However, because of adverse reactions of DTwP in 1974 and 1975, mass vaccinations were temporarily suspended in 1975, 2) and the incidence of pertussis rose to 11.3 cases per 100000 population in 1979. 2,3) In 1981, an acellular pertussis vaccine (aP), composed mainly of pertussis toxin (PT) and filamentous hemagglutinin (FHA) from B. pertussis strain Tohama, was introduced and widely distributed.…”

Section: Introductionmentioning

confidence: 99%

“…2,3) However, because of adverse reactions of DTwP in 1974 and 1975, mass vaccinations were temporarily suspended in 1975, 2) and the incidence of pertussis rose to 11.3 cases per 100000 population in 1979. 2,3) In 1981, an acellular pertussis vaccine (aP), composed mainly of pertussis toxin (PT) and filamentous hemagglutinin (FHA) from B. pertussis strain Tohama, was introduced and widely distributed. 4) As a result, the incidence of pertussis fell again, reaching about 0.4 cases per 100000 population in 1988.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of Acellular Pertussis Vaccine Against Various Strains of Bordetella Pertussis in a Murine Model of Respiratory Infection.

Watanabe

Nagai

2002

JOURNAL OF HEALTH SCIENCE

View full text Add to dashboard Cite

The protective effects of an acellular pertussis vaccine were investigated in a murine model of respiratory infection (aerosol challenge model) with various strains of Bordetella pertussis (B. pertussis) as challengers. There were no significant differences in terms of the time course of increases in numbers of bacterial cells in mouse lungs after aerosol challenge among the tested phase I strains. The vaccine had a strong protective effect against of B. pertussis strain Tohama the phase I strain used for production of the vaccine, however was less effective against other clinical isolates of pertussis. Our data suggest that a novel vaccine(s) should be developed from the strains derived from current clinical isolates to eliminate the incidence of pertussis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Acellular Pertussis Vaccine Against Various Strains of Bordetella Pertussis in a Murine Model of Respiratory Infection.

Watanabe

Nagai

2002

JOURNAL OF HEALTH SCIENCE

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5][6][7] Filamentous hemagglutinin (FHA), pertussis toxin (PT), pertactin (PRN), and fimbriae are all effective components of pertussis vaccines.…”

Section: Introductionmentioning

confidence: 99%

Differing Protective Effects of Acellular Pertussis Vaccines in Neonatal and Young Mice in a Murine Model of Respiratory Infection.

Watanabe

Komatsu

Sato

et al. 2002

JOURNAL OF HEALTH SCIENCE

View full text Add to dashboard Cite

The protective effects on neonatal (3.5 weeks old) and young mice (7 weeks old) of eight pertussis vaccines prepared from various components at various concentrations were investigated in a murine model of respiratory infection (aerosol challenge model). Neonatal mice were more sensitive than young mice to infection by Bordetella pertussis after aerosol challenge. In young mice with all vaccines, there were significant differences between immunized mice and control mice. The efficacy of vaccines was increased by the inclusion of additional filamentous hemagglutinin (FHA), pertussis toxin (PT), or pertactin (PRN) in the basic vaccine (FHA : PT : PRN, 7 : 2 : 1, w/w). An elevated level of FHA strongly increased the efficacy of the vaccine in young mice. It was, however, more difficult to induce protection against B. pertussis in neonatal mice than in young mice, irrespective of the levels of the various components in the vaccines. Our data suggest that pertussis vaccines are less effective in neonatal mice than in young mice, as assessed by the aerosol challenge model.

show abstract

Clinical Reactions and Immunogenicity of the BIKEN Acellular Diphtheria and Tetanus Toxoids and Pertussis Vaccine in 4- Through 6-Year-Old US Children

Bernstein¹

1992

Arch Pediatr Adolesc Med

View full text Add to dashboard Cite

Current epidemiology of pertussis in Japan

Cited by 34 publications

References 0 publications

Effect of Acellular Pertussis Vaccine Against Various Strains of Bordetella Pertussis in a Murine Model of Respiratory Infection.

Effect of Acellular Pertussis Vaccine Against Various Strains of Bordetella Pertussis in a Murine Model of Respiratory Infection.

Differing Protective Effects of Acellular Pertussis Vaccines in Neonatal and Young Mice in a Murine Model of Respiratory Infection.

Clinical Reactions and Immunogenicity of the BIKEN Acellular Diphtheria and Tetanus Toxoids and Pertussis Vaccine in 4- Through 6-Year-Old US Children

Contact Info

Product

Resources

About